The story
Portugal’s 2018 medical-cannabis law established a framework for prescribed cannabis medicines, preparations and substances supplied through pharmacies. Published on 18 July, it took effect on 1 August under its commencement clause. This was a distinct reform from the personal-use decriminalisation introduced in 2001.[1]
A prescription had to meet treatment conditions
The law reserved prescribing for cases where conventional authorised medicines did not produce the expected result or caused significant adverse effects. INFARMED was responsible for approving appropriate indications. The prescription had to identify the patient and doctor, product, quantity, dose and method of administration.[1]
Pharmacy dispensing included an identity check. The patient could hold and transport the prescribed quantity for personal treatment. These provisions gave patients a defined route to authorised products, rather than permission to obtain any cannabis product from an informal supplier.[1]
Product permission and activity licences served different purposes
INFARMED’s guidance distinguishes authorised medicines from cannabis preparations and substances needing a marketing authorisation. An interested company must submit a product for assessment before it can enter the pharmacy market. Cultivation, manufacture, wholesale distribution, imports and exports also require their respective permissions.[2]
The regulator’s later review describes how international companies’ interest in Portugal during 2016–2017 preceded the specific medical framework. A 2021 regulation then set out the requirements and procedures for licensing the activities along that supply chain, including coordination over security arrangements.[3]
Pharmacy access depended on authorised products
INFARMED explains that any doctor may prescribe within the approved conditions, while pharmacies supply against a prescription. The regulator directs people to its Infomed database to check which cannabis preparations have marketing authorisations. Approval and a particular pharmacy’s stock are separate practical questions.[2]
The agency also operates safety monitoring for these preparations. Suspected adverse reactions are assessed, and patients and health professionals can report them through its reporting system. This places cannabis preparations within a supervised treatment process that continues after authorisation.[2]
The law kept recreational supply outside the reform
The 2018 framework concerned medical use and the activities needed to supply it. Its product and prescription controls did not authorise general recreational cultivation or retail.[1][4]
The Portugal profile therefore keeps the medical route separate from personal-use administrative proceedings and the criminal rules on growing or supplying cannabis. Its decriminalisation history describes the earlier change that shaped those personal-use proceedings.[4][5]
Score by segment 0 to 10
- Possession · 25%3 → 3
- Personal cultivation · 25%1 → 1
- Punishment & enforcement · 20%5 → 5
- Sharing & gifting · 10%1 → 1
- Consumption · 10%3 → 3
- Legal access · 10%0 → 1+1
The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Portugal's current scores.
References
- Diário da República — Law 33/2018Articles 1–13; publication 18 July 2018, commencement 1 Augustarchived
- INFARMED — Cannabis for medicinal purposesPrescribing, pharmacy dispensing, marketing authorisations and safety monitoringarchived
- INFARMED — Medicinal cannabis activity, 2025Regulatory background and licensing arrangementsarchived
- Lisbon District Prosecutor-General — Decree-Law 15/93, current consolidationArticles 21 and 40archived
- Lisbon District Prosecutor-General — Law 30/2000, current consolidationArticle 2archived
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.